Therefore, further studies are needed to explore the preliminary link between NLRC4-mediated IL-1β secretion and tumor progression, potentially positioning the NLRC4-IL-1β pathway as a potential therapeutic target for inhibition of glioma and other cancers. The gene discussed is IL1B; the disease is neoplasm.